Dr. Lal PathLabs Ltd (LALPATHLAB) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Dr Lal PathLabs reported a strong Q1 FY26, driven by steady volume momentum and favorable test mix.
- Revenue grew by 11.3% YoY, reaching 670 crore, while profit after tax saw a significant increase of 24.3% to 134 crore.
- Sample volumes increased by 10.7% and patient volumes by 5.3%.
- Swasthya portfolio contributed 27% of revenue, up from 25% in Q1 FY25.
- The company declared an interim dividend of 6 per share.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.